Andrae Vandross
机构: Yale University School of Medicine
每年引用次数
引用次数
引用: 1,019
H-指数: 9
I10-指数 : 9
出版物: 53
Case Reports in the Age of Twitter
Adam S. Cifu , Andrae L. Vandross , Vinay Prasad
The American Journal of Medicine 132 ( 10)
16
2019
Name-Calling
Andrae Vandross MD
Journal of General Internal Medicine 28 ( 1) 162 -163
2013
A phase 1/2 study of DCC-3116 as a single agent and in combination with trametinib in patients with advanced or metastatic solid tumors with RAS or RAF mutations.
Anthony W Tolcher , David S Hong , Andrae Lavon Vandross , Charles M Psoinos
Smpte Journal
2022
A phase 1/2 study of ONCT-534, a dual-action androgen receptor inhibitor (DAARI), in patients with metastatic castration-resistant prostate cancer.
Evan Y Yu , Salim Yazji , Yisrael Katz , Elisabeth Coates
Journal of Clinical Oncology 42 ( 4_suppl) TPS241 -TPS241
1
2024
A phase 1/2, first-in-human trial of ZB131, a novel antibody targeting cancer-specific plectin (CSP) in advanced solid tumors.
David Sommerhalder , Sarina A Piha-Paul , Meredith Pelster , Mitesh J Borad
Journal of Clinical Oncology 41 ( 16_suppl) 3083 -3083
1
2023
First-in-human study of PC14586, a small molecule structural corrector of Y220C mutant p53, in patients with advanced solid tumors harboring a TP53 Y220C mutation
Ecaterina Elena Dumbrava , Melissa Lynne Johnson , Anthony W Tolcher , Geoffrey Shapiro
J. Clin. Oncol 40 ( 16) 3003 -3003
44
2022
Phase 1/2 study of XTX101, a masked, tumor-selective Fc-modified anti-CTLA4, in patients with advanced solid tumors.
Diwakar Davar , John George Knecht , Andrae Lavon Vandross , Cesar Augusto Perez
Journal of Clinical Oncology 41 ( 16_suppl) e14685 -e14685
2023
Early safety and efficacy from a phase I open-label clinical study of LVGN7409 (CD40 agonist antibody) in patients with advanced or metastatic malignancies.
Siqing Fu , Andrae Lavon Vandross , Yi Hsin Hsu , Naiyi Shi
Journal of Clinical Oncology 40 ( 16_suppl) e14501 -e14501
3
2022
First-in-human dose-escalation study of NBF-006, a novel investigational siRNA targeting GSTP, in patients with non-small cell lung, pancreatic, or colorectal cancer.
Anthony W Tolcher , Alexander I Spira , John J Nemunaitis , Andrae Lavon Vandross
Journal of Clinical Oncology 41 ( 16_suppl) 3084 -3084
2
2023
A phase 1/2 dose escalation/expansion study of OR2805 alone or in combination in subjects with advanced solid tumors.
Anthony W Tolcher , Andrae Lavon Vandross , Justin C Moser , Michael S Gordon
Journal of Clinical Oncology 40 ( 16_suppl) TPS2693 -TPS2693
1
2022
CBX-12-101: A first-in-human study of CBX-12, an alphalex peptide drug conjugate (PDC) in patients with advanced or metastatic solid tumors
F Meric-Bernstam , JP Eder , A Vandross , M Gara
European Journal of Cancer 174 S7 -S8
2022
A Phase 1 study of the anti-tissue factor antibody-drug conjugate XB002 in patients with advanced solid tumors (JEWEL-101): initial results from the dose-escalation stage
S Ulahannan , ML Johnson , H Park , A Vandross
European Journal of Cancer 174 S92 -S93
2
2022
87TiP Phase I expansion study of the tissue factor (TF)–targeting antibody-drug conjugate (ADC) XB002 as a single-agent and combination therapy in patients with advanced solid tumors (JEWEL-101)
S Ulahannan , ML Johnson , MC Weiss , A Vandross
Annals of Oncology 34 S1500 -S1501
2023
A decade of reversal
V Prasad , A Vandross , C Toomey , M Cheung
an analysis of 146 contradicted medical practices 2013 88 -88
6
1076TiP First-in-human study of ABBV-514 as monotherapy and in combination with budigalimab in patients with advanced solid tumors
S Babu , S Kondo , N Ammakkanavar , AI Spira
Annals of Oncology 34 S647 -S648
2023
450O Initial monotherapy results of a phase I first-in-human study of ULK1/2 inhibitor DCC-3116 alone and in combination with MAPK pathway inhibition
AW Tolcher , DS Hong , A Vandross , R Amaravadi
Annals of Oncology 33 S741 -S742
2022
Updated phase 1 results from the PYNNACLE Phase 1/2 study of PC14586, a selective p53 reactivator, in patients with advanced solid tumors harboring a TP53 Y220C mutation
Alison M Schram , Geoffrey I Shapiro , Melissa L Johnson , Anthony W Tolcher
MOLECULAR CANCER THERAPEUTICS 22 ( 12)
1
2023
Abstract LB_A25: Updated Phase 1 results from the PYNNACLE Phase 1/2 study of PC14586, a selective p53 reactivator, in patients with advanced solid tumors harboring a TP53 Y220C mutation
Alison M Schram , Geoffrey I Shapiro , Melissa L Johnson , Anthony W Tolcher
Molecular Cancer Therapeutics 22 ( 12_Supplement) LB_A25 -LB_A25
2023
Cohort expansion from the phase 1 JEWEL-101 study investigating the tissue factor-targeting antibody-drug conjugate XB002 in patients with advanced solid tumors: Pancreatic and esophageal cancer cohorts.
Susanna Varkey Ulahannan , Melissa Lynne Johnson , Mia C Weiss , Andrae L Vandross
Journal of Clinical Oncology 42 ( 3_suppl) TPS421 -TPS421
2024
An open-label, multicenter phase 1 study to characterize safety, tolerability, preliminary antitumor activity, and pharmacokinetics of VIP236 monotherapy in patients with advanced cancer.
Andrae L Vandross , Brian N Stein , Jermaine Coward , Sunil Sharma
Journal of Clinical Oncology 42 ( 16_suppl) TPS3168 -TPS3168
2024